VIVUS, Inc. (VVUS) Stock Is At 52-Week Low Now

October 13, 2017 - By Clifton Ray

Investors sentiment increased to 1.27 in Q2 2017. Its up 0.14, from 1.13 in 2017Q1. It increased, as 5 investors sold VIVUS, Inc. shares while 21 reduced holdings. 16 funds opened positions while 17 raised stakes. 37.61 million shares or 3.37% more from 36.39 million shares in 2017Q1 were reported.
Northwestern Mutual Wealth Mngmt owns 116 shares for 0% of their portfolio. The Massachusetts-based Geode Capital Mngmt Limited Com has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Blackrock stated it has 2.16M shares or 0% of all its holdings. Sei Invests has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Ajo Lp accumulated 2.73M shares. Acadian Asset Lc accumulated 1.84M shares. Captrust Financial reported 3,000 shares. Cornerstone Lc invested 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Moreover, Tower Cap Ltd (Trc) has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 100 shares. Susquehanna Interest Grp Inc Llp has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Plante Moran Fincl Advsrs Limited Liability Com accumulated 190 shares. Menta Capital Limited Liability Corp has 286,972 shares. Creative Planning reported 10,656 shares. Group Inc Inc One Trading L P holds 33,397 shares. Glenmede Trust Na has 0% invested in VIVUS, Inc. (NASDAQ:VVUS).

The stock of VIVUS, Inc. (NASDAQ:VVUS) hit a new 52-week low and has $0.77 target or 9.00 % below today’s $0.85 share price. The 7 months bearish chart indicates high risk for the $89.97 million company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $0.77 price target is reached, the company will be worth $8.10M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 633,435 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 7.14% since October 13, 2016 and is downtrending. It has underperformed by 23.84% the S&P500.

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.13 EPS on November, 8.They anticipate $0.04 EPS change or 44.44 % from last quarter’s $-0.09 EPS. After having $-0.13 EPS previously, VIVUS, Inc.’s analysts see 0.00 % EPS growth.

VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating by Zacks given on Wednesday, August 5. RBC Capital Markets maintained the shares of VVUS in report on Friday, July 31 with “Outperform” rating. WallachBeth Capital upgraded VIVUS, Inc. (NASDAQ:VVUS) on Thursday, November 5 to “Buy” rating.

VIVUS, Inc. is a biopharmaceutical company. The company has market cap of $89.97 million. The Firm operates in the development and commercialization of therapeutic products segment. It has a 2.8 P/E ratio. It provides over two therapies approved by the Food and Drug Association , which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.